Skip to main content

Table 5 Viruses identified at baseline in trial participants

From: Efficacy and safety of iota-carrageenan nasal spray versus placebo in early treatment of the common cold in adults: the ICICC trial

  I-C Placebo
Total number of patients tested (N) 98 97
Number of virus positive patientsa, b (N, %) 53 (54.1) 54 (55.7)
Influenza Type A 1 (1.0) 2 (2.1)
Picornavirus (including HRV and HEV) 30 (30.6) 28 (29.3)
 Positive qualitative picornavirus assay 26 (26.5) 26 (26.8)
 Positive qualitative enterovirus assay 2 (2.0) 0 (0.0)
 Positive resultc on panenterhino/Ge/08 assay 27 (27.6) 28 (28.9)
 Quantifiable result on panenterhino/Ge/08 assay 22 (22.4) 24 (24.7)
Human metapneumovirus 0 (0.0) 1 (1.0)
Coronavirus 23 (22.4) 19 (19.6)
 Coronavirus 229E 1 (1.0) 2 (2.0)
 Coronavirus HKU1 1 (1.0) 2 (2.1)
 Coronavirus NL63 9 (9.2) 4 (4.1)
 Coronavirus OC43 12 (12.2) 11 (11.3)
Adenovirus 0 (0.0) 2 (2.1)
Respiratory syncytial virus 0 (0.0) 1 (1.0)
Parainfluenza 5 (5.1) 5 (5.2)
 Type 1 3 (3.1) 0 (0.0)
 Type 2 1 (1.0) 1 (1.0)
 Type 4 1 (1.0) 4 (4.1)
  1. Categories are not exclusive; patients may appear in more than one category
  2. aEight patients were positive for 2 different viruses
  3. bNo patient tested positive for influenza B, human bocavirus, human paraecho virus, or parainfluenza 3
  4. cDetectable (quantifiable or non-quantifiable) result at baseline